Reported about 17 hours ago
Connecticut has enacted a law aimed at reducing state spending on weight-loss drugs by petitioning the federal government to allow for the production of generic GLP-1 medications, like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. The petition targets Health and Human Services Secretary Robert F. Kennedy Jr., leveraging federal patent law to contract with generic manufacturers. With rising costs impacting state health programs, Connecticut hopes its initiative not only lowers expenses but also paves the way for similar efforts in other states.
Source: YAHOO